Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 50,000 shares of common stock on August 12, 2025, at a price of $86.07, totaling $4,303,500.
On the same day, Carey also exercised options to acquire 50,000 shares of ANI Pharmaceuticals at a price of $46.49, for a total value of $2,324,500. These options stemmed from an award where 25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020. The $1.81 billion market cap company has received a "GREAT" financial health score from InvestingPro’s comprehensive analysis.
Following these transactions, Carey directly owns 180,863 shares of ANI Pharmaceuticals Inc. For deeper insights into insider trading patterns and 15+ additional ProTips about ANI Pharmaceuticals, including detailed valuation metrics and growth projections, visit InvestingPro.
In other recent news, ANI Pharmaceuticals reported robust financial results for the second quarter of 2025, with revenue reaching $211.4 million, surpassing the forecast of $187.34 million. The company also achieved an adjusted non-GAAP earnings per share (EPS) of $1.80, exceeding the consensus estimate of $1.41. This impressive performance was largely driven by the Cortrophin Gel product line, which generated $81.6 million in revenue, marking a 66% year-over-year increase and a 54% sequential rise from the previous quarter. Following these results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS. Analyst firm H.C. Wainwright responded by raising its price target for ANI Pharmaceuticals to $93 from $84, maintaining a Buy rating. Similarly, Truist Securities increased its price target to $77 from $65, while maintaining a Hold rating. These developments reflect the company’s strong market performance and positive outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.